Author

Arnab Mukherjee

Sensei Biotherapeutics (United States)ORCID 0000-0002-2147-5182Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Arnab Mukherjee1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adejumoke M. OnumajuruiD· 1 shared Edward Htun van der HorstiD· 1 shared F. Donelson SmithiD· 1 shared Kanam MalhotraiD· 1 shared Thomas ThistediD· 1 shared Vikas SaxenaiD· 1 shared Yuliya KleschenkoiD· 1 shared Zhi-Gang JiangiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adejumoke M. OnumajuruORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Dual Targeting for Enhanced Tumor Immunity: Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-Cell Activation

Thomas Thisted, F. Donelson Smith, Zhi-Gang Jiang, Zuzana Biesová, Adejumoke M. Onumajuru, Yuliya Kleschenko, Kanam Malhotra, Vikas Saxena, Arnab Mukherjee, Edward Htun van der Horst

This paper develops pH-selective CD28xVISTA bispecific antibodies that enhance T-cell activation in the tumor microenvironment while minimizing systemic side effects.

bioRxiv · Apr 7, 2025 · PreprintCancer Biology